A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol consumed when someone on the drug does drink

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink less alcohol.

A new study published in the JAMA Psychiatry gives the strongest evidence that semaglutide — the active ingredient in Ozempic and the weight-loss drug Wegovy — could genuinely help individuals struggling with alcohol addiction drink less and crave alcohol less frequently.

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise benefits besides shedding pounds soon surfaced. One of those – that the medication changed drinking and smoking habits overnight – understandably piqued the interest

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

But when averaging the number of drinks only on the days alcohol was consumed, the reduction was greater in the Ozempic group. And over time, there was a greater reduction in heav